fasudil has been researched along with Cancer of Mouth in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral squamous cell carcinoma (OSCC) is the most malignant lesion occurring in the head and neck." | 1.42 | HA-1077 inhibits cell migration/invasion of oral squamous cell carcinoma. ( Crema, VO; Moreira Carboni, Sde S; Pinheiro, NM; Rodrigues Lima, NA; Tavares-Murta, BM, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moreira Carboni, Sde S | 1 |
| Rodrigues Lima, NA | 1 |
| Pinheiro, NM | 1 |
| Tavares-Murta, BM | 1 |
| Crema, VO | 1 |
1 other study available for fasudil and Cancer of Mouth
| Article | Year |
|---|---|
HA-1077 inhibits cell migration/invasion of oral squamous cell carcinoma.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actin Cytoskeleton; Antineoplastic Agents; Carcinoma, | 2015 |